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The S100A4 protein has been associated with increased metastatic capacity of cancer cells, and recent studies have suggested a
correlation between the expression level of S100A4 and the prognostic outcome for patients with various types of cancer. The
knowledge about the mechanisms underlying the metastasis-promoting effects is still limited, and the aim of the present study was to
elucidate signal transduction pathways involved in the regulation of S100A4. After treatment of human carcinoma cells with
interferon-gamma (IFN-g), we observed downregulation of S100A4 both at mRNA and protein levels. The effect was not dependent
on IFN-g-induced apoptosis or IFN-g-mediated cell cycle arrest. Moreover, IFN-g-mediated decrease in mRNA stability could not
account for the observed decrease in S100A4 transcript level. Finally, microarray analysis suggests ISGF3G, ETV5, ZNF133 and
CEBPG as possible candidate genes involved in IFN-g-mediated repression of S100A4.
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Several studies have associated the S100A4 protein with increased
metastatic capacity of cancer cells (Davies et al, 1993; Mælandsmo
et al, 1996; Levett et al, 2002), and more recently a correlation
between the level of S100A4 protein and prognostic outcome has
been reported in various types of cancer (lung gall bladder,
oesophageal, gastric, breast and colon) (Kimura et al, 2000;
Rudland et al, 2000; Yonemura et al, 2000; Ninomiya et al, 2001;
Gongoll et al, 2002; Nakamura et al, 2002). Several laboratories
have studied the involvement of S100A4 in invasion and
metastasis, but little is still understood of the mechanism by
which it exerts the metastasis-promoting effects. Previously, we
reported an association between S100A4 expression, matrix
metalloproteinase activity and the metastatic capacity of human
osteosarcoma cells (Bjornland et al, 1999). Other studies have
reported interactions between S100A4 and cytoskeletal associated
proteins, suggesting a function in cell motility, thereby contribut-
ing to increased metastatic potential (Davies et al, 1993; Watanabe
et al, 1993; Kriajevska et al, 1998, 2000; Ambartsumian et al, 2001).
In addition, Ambartsumian et al (2001) reported that when
secreted from tumour cells, S100A4 could cause cancer progres-
sion through stimulation of angio-genesis. Finally, S100A4 has
been found to interact with p53, S100A1 and, recently, liprin beta 1
(Wang et al, 2000; Chen et al, 2001; Kriajevska et al, 2002).
Interaction with p53 would implicate a role for this S100 protein in
fundamental cellular events like cell cycle regulation and
apoptosis, while S100A4 interaction with liprin beta 1 points to a
role in cytoskeletal dynamics and cell adhesion.
The aim of the present study was to identify mediators involved
in the regulation of S100A4 expression, and to elucidate implicated
signal transduction pathways. Several signal inducers were tested,
but only interferon-gamma (IFN-g) revealed any effects, resulting
in reduction in S100A4 mRNA and protein levels in all tested cell
lines. Upon cytokine binding, the IFN-g-receptor subunits dimerise
and thereby activate the intrinsic kinase leading to phosphorylation
of the associated Jak-1 and Jak-2. These kinases subsequently
phosphorylate STAT1, which when phosphorylated forms homo-
dimers, translocates to the nucleus and activates transcription by
binding to the interferon-gamma-activated sequence (GAS). This
binding affects gene expression that ultimately accounts for the
diverse cellular effects induced by IFN-g, including the well-
documented cell cycle arrest and/or apoptosis (reviewed by Boehm
et al, 1997; Stark et al,1 9 9 8 ;S a m u e l ,2 0 0 1 ) .
The possibility that the observed regulation of S100A4 expres-
sion by IFN-g was a secondary event caused by IFN-g-induced cell
cycle arrest or apoptosis was excluded, and indications for reduced
transcription caused by upstream factors were obtained. In search
for factors instrumental for the observed repression, microarray
analysis revealed a number of candidate genes including ISGF3G,
ETV5, ZNF133 and CEBPG.
MATERIALS AND METHODS
Materials
Interferon-gamma and thapsigargin were from Calbiochem
(Nottingham, UK). PD98059 was from New England Biolabs
(Beverly, MA, USA). Tumour necrosis factor-alpha (TNF-a),
actinomycin D and transforming growth factor-beta (TGF-b) were
all from Sigma Chemical Company (St Louis, MO, USA).
Cell culture
All the examined cell lines (OHS (Fodstad et al, 1986), II-11b (anti-
S100A4-ribozyme transfected OHS cells, Maelandsmo et al, 1996), Received 6 January 2003; revised 7 April 2003; accepted 10 April 2003
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Manassas, VA, USA) and PM1 (breast carcinoma, established in
our lab)) were cultivated in RPMI-1640 (Bio Whittaker, Verviers,
Belgium) containing 10% fetal bovine serum (FBS; Biochrome KG,
Berlin, Germany), 50 IE penicillin, 0.1mgml
 1 streptomycin (Bio
Whittakker, Verviers, Belgium), 20mM HEPES and 2.0mM
Glutamax (GIBCO BRL, Life Technologies, Paisley, UK). For all
experiments, subconfluent cultures were trypsinated and seeded at
2 10
4cellscm
 2 in 25 or 75cm
2 culture flasks, except for
proliferation and apoptosis experiments where 5000 cells per well
were seeded in 96-well cell culture plates. After overnight
incubation, the culture medium was replaced with medium in
the presence or absence of IFN-g and harvested as indicated in the
text.
Northern blotting
Total RNA was isolated by a single-step RNA isolation method
using Trizol
s (GIBCO BRL, Life Technologies, Paisley, UK)
according to the manufacturer’s protocol. A measure of 5mgo f
total RNA was separated by electrophoresis through 1% agarose
gels containing 6.6% formaldehyde in 0.02 M NaH2PO4 (pH 6.6)
and transferred onto Hybond-Nþ membranes (Amersham
Pharmacia Biotech, Uppsala, Sweden). After baking for 2h and
subsequent UV crosslinking, filters were hybridised with DNA
probes labelled with
32P by the random priming technique
(Feinberg and Vogelstein, 1983). The hybridisations were carried
out in 0.5 M Na2HPO4 (pH 7.2) and 1% SDS according to Church
and Gilbert (1984). For multiple hybridisations, the bound probe
was removed by incubating the filters twice for 5min in 0.1 SSC
and 0.1% SDS at 95–1001C. To correct for an uneven amount of
RNA loaded in each lane, filters were rehybridised with a kinase
labelled oligonucleotide probe specific for human 18S rRNA. The
mRNA levels were measured using a Storm PhosphoImage-
scanner (Amersham Biosciences, Sunnyvale, CA, USA) and
quantified using an ImageQuant software package (Amersham
Biosciences, Sunnyvale, CA, USA). The cDNA probe for S100A4
was kindly provided by Dr CW Heizmann, University Hospital of
Zu ¨rich, Switzerland.
Western blotting
Protein lysates were prepared in 50mM Tris-HCl (pH 7.5),
containing 150mM NaCl and 0.1% NP-40 with 2mgml
 1 pepstatin,
aprotinin (Sigma Chemical company, St Louis, MO, USA) and
leupeptin (Roche Diagnostics, Mannheim, Germany). Total protein
lysate (40mg) from each sample was separated by 12% sodium
dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–
PAGE), and transferred onto Immobilon-P membranes (Millipore,
Bedford, MA, USA) according to the manufacturer’s manual. As a
loading and transfer control, the membranes were stained with
0.1% amidoblack. The membranes were subsequently incubated in
20mM Tris-HCl (pH 7.5), containing 0.5 M NaCl and 0.25% Tween
20 (TBST) with 10% dry milk (blocking solution) before
incubation with rabbit polyclonal anti-S100A4 (diluted 1:300,
DAKO, Glostrup, Denmark), rabbit polyclonal anti-STAT1p91
(diluted 1:1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA),
and mouse monoclonal anti-alpha-tubulin (diluted 1:250, Amer-
sham Life Science, Buckinghamshire, England) in TBST containing
5% dry milk. When immunostaining with rabbit polyclonal
antiphospho-STAT1 (Tyr-701) (diluted 1:1000, Cell Signaling
Technology, Beverly, MA, USA), TBST containing 0.05% Tween
20 was used. After washing, the immunoreactive proteins were
visualised using horseradish peroxidase-conjugated secondary
antibodies (diluted 1:5000 DAKO, Glostrup, Denmark), and the
enhanced chemiluminescense system (Amersham Pharmacia
Biotech, Buckinghamshire, England).
Half-life of S100A4 protein
The half-life of the S100A4 protein was estimated by means of
35S-incorporation. The cell cultures were treated with methionine-
free culture medium for 30min before
35S-methionine
(20mCiml
 1, Amersham Pharmacia Biotech, Buckinghamshire,
England) was added. After 1h incubation, the medium was
substituted with ordinary growth medium. Cells were harvested
at different time points (0–48h). Protein lysates were prepared
and subjected to immunoprecipitation using 15mg rabbit poly-
clonal anti-S100A4 antibody. After collecting the immunoprecipi-
tate with protein A-sepharose beads (Sigma-Aldrich, St Louis, MO,
USA), the precipitates were resolved on a 12% SDS–PAGE gel. The
dried gel was exposed for autoradiography overnight and the
intensities of the S100A4 bands were subsequently analysed using a
Personal Laser Densitometer SI (Amersham Biosciences,
Sunnyvale, CA, USA).
Cell proliferation
The proliferation in cell cultures was estimated by means of
CellTiter 96
s AQueous One Solution Reagent (MTS) (Promega,
Madison, WI, USA) according to the manufacturer’s manual. The
absorbance at 490nm was recorded using a Wallac 1420 Victor
2
Multilabel counter (Wallac Oy, Turku, Finland). All experiments
were conducted at least in duplicate and repeated three times.
Flow cytometry
Cell cycle distribution of control and IFN-g-treated cell cultures
were analysed by flow cytometry. The cultures were trypsinated,
fixed in ice-cold methanol and stored at  201C. Prior to analysis
on a FACStarþ flow cytometer (Becton Dickinson, San Jose, CA,
USA), cells were washed in phosphate-buffered saline (PBS) and
resuspended in 2mgml
 1 Hoechst 33258 in PBS. Data analysis was
carried out using the Modfit software (Verity Software House, Inc.,
Topsham, ME, USA). All experiments were conducted at least in
duplicate and repeated three times.
Apoptosis
The amount of cells undergoing programmed cell death was
estimated using the Cell Death Elisa
Plus Kit (Roche Diagnostics,
Mannheim, Germany), according to the manufacturer’s manual.
All assays were performed at least twice and in duplicate.
Microarray analysis
Microarray analysis using in-house printed slides containing
11.5k polymerase chain reaction (PCR)-amplified cDNAs was
performed hybridising with cDNA probes prepared from control
and IFN-g-treated (10Uml
 1 for 48h) OHS and II-11b cell
cultures. Total RNA was isolated using the GenElute Mammalian
Total RNA Kit (Sigma Chemical Co., St Louis, MO, USA). Each
probe was made using Cy3-dUTP and Cy5-dUTP in cDNA
labelling reactions starting with 30mg total RNA. Both untreated
and IFN-g-treated cultures were labelled with the two fluorophores
and details for probe preparation and hybridisation conditions are
included in the protocol located at http://www.med.uio.no/dnr/
microarray. Totally, five hybridisations were performed (three
OHS cDNA and two cDNA prepared from II-11b RNA), and the
results are presented as average ratios from at least four
hybridisations. Hybridised slides were scanned at a constant laser
power of 100% for Cy3 and Cy5 and variable photomultiplier
settings in a Scan Array 4000 instrument (GSI Lumonics, Inc.,
Billerica, MA, USA). Images obtained after scanning were
imported to the GenePix Pro 3.0 software (Axon Instruments,
Inc., Union City, CA, USA) for further analysis, including spot
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sintensity measurements. Spots carrying technical-based artefacts
were excluded manually.
RESULTS
Transcriptional regulation of S100A4
In attempts to elucidate cellular pathways involved in the
regulation of S100A4 gene expression, four cell lines with S100A4
protein levels varying from low (II-11b and PM1) to medium
(WiDr) and high (OHS) were treated with different signal inducers.
In initial screening experiments, effects were monitored at the
transcriptional level in PM1, WiDr and OHS cells. Under the
experimental conditions used, gene expression was not influenced
by the MEK1-inhibitor PD98059, the calcium ionophore thapsi-
gargin, TNF-a or TGF-b (Figure 1). In contrast, IFN-g induced a
significant suppression of S100A4 transcription in all the cell lines
(Figure 2A), and 12–24h later, a corresponding downregulation of
S100A4 was observed at the protein level. As measured by
densitometric scanning, the S100A4 mRNA level was reduced
four-fold in the high expressing OHS cells, and three-fold in the
II-11b, WiDr and PM1 cells (Figures 1 and 2). The S100A4
response was observed at an earlier time point and at a lower dose
in the osteosarcoma compared to the carcinoma cell lines (Figure
2A and B). Thus, maximal response was seen at 48h with 10Uml
 1
in the OHS and II-11b cultures, whereas for PM1 and WiDr cells,
200Uml
 1 for 72h was required to reach the same level of
response. Notably, both WiDr and PM1 cells responded with
induction of STAT1 after incubation with 50Uml
 1 IFN-g for 48h
(results not shown), suggesting that the difference in S100A4
response could not be explained by increased sensitivity to IFN-g
in the osteosarcoma cells in general. The osteosarcoma cells did
not show detectable downregulation of S100A4 at doses lower than
10Uml
 1 IFN-g.
Activation of the Jak/STAT1 signalling pathway
It is well documented that STAT1 gene expression is induced upon
activation of the IFN-g/Jak/STAT1 signalling pathway (Boehm et al,
1997) and, in agreement with this, an induction of STAT1 was
observed in all the examined cell lines (Figure 2B). To further
confirm activation of STAT1, lysates from IFN-g-treated OHS cells
were stained with antiphospho-STAT1 (Tyr-701) antibody
(Figure 3). The results showed that the treatment induced
phosphorylation of STAT1 within a few minutes, thus confirming
an active signalling pathway.
Half-life of S100A4 protein
In order to explain the time gap between the observed down-
regulation of S100A4 mRNA and the corresponding decline at the
protein level, we used a radioactive incorporation assay to
determine the half-life of the protein. The estimated half-life of
S100A4 in OHS was 24h (results not shown), which might explain
the observed lag period between mRNA and protein response
(Figure 2A and B).
Effects on cell proliferation and cell cycle distribution
As measured by the MTS assay, IFN-g inhibited proliferation in
OHS and WiDr cells by approximately 50%, while II-11b and PM1
cells were less influenced by the treatment, showing only 13 and
17% reduction in proliferation rate, respectively (Table 1). The cell
cycle distribution of IFN-g-treated cell cultures was analysed by
flow cytometry. Both treated and untreated WiDr cells demon-
strated an accumulation of cells in the G0/G1 phase. This may be
explained by the long incubation period (72h), while neither the
treatment nor the long incubation time had any clear effect on cell
cycle distribution in the OHS, II-11b or PM1 cell lines.
IFN-c-mediated induction of apoptosis
To study the possible effects of IFN-g treatment on apoptosis, an
immunoreagent-based apoptosis detection kit was utilised. A 3.5-
and 5.7-fold increase in apoptosis was seen for the OHS and WiDr
cell lines, respectively, as compared to the corresponding control
cultures. For the low S100A4-expressing cell line II-11b, a 1.6-fold
increase in apoptosis was found, whereas the fraction of apoptotic
PM1 cells was unchanged by the treatment. These results are in
agreement with the cell survival data. Thus, whereas the II-11b and
PM1 were only slightly influenced by IFN-g, OHS and WiDr cell
survival was reduced to approximately 50% (Table 1). Notably,
independent of the induction of apoptosis, S100A4 expression was
downregulated by IFN-g in all the cell lines.
_ + _ + _ + _ + _ +
PD98059 TGF- Thapsigargin TNF- IFN-
S100A4
S100A4
S100A4
18S
18S
18S
OHS
PM1
WiDr
Figure 1 Representative Northern blots showing effects of different mitogens on the expression of S100A4. The OHS, PM1 and WiDr cell lines were
incubated with 20mM PD98059 for 24h, 0.2nM TGF-b for 24h, 0.5ngml
 1 thapsigargin for 24h, 10ngml
 1 TNF-a for 48h or 200Uml
 1 IFN-g for 48h.
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To study whether IFN-g-mediated downregulation of S100A4
expression could be explained by decreased mRNA stability, OHS
cells were incubated with IFN-g for 24h before adding actinomycin
D, a general inhibitor of transcription. Cells were harvested at
different time points (0–24h) after the addition of actinomycin D,
total RNA was extracted and the amount of S100A4 transcript was
analysed by means of Northern blotting and densitometric
scanning. As shown in Figure 4, no significant differences in
S100A4 mRNA decay between IFN-g-treated and untreated
cultures were demonstrated.
IFN-c-responsive genes as measured by cDNA microarray
To search for candidate genes involved in IFN-g-mediated
repression of S100A4 transcription, cDNA microarray analysis
was performed, focusing on DNA-binding genes/transcription
factors/repressors that were significantly up- or downregulated
by the treatment. By defining three-fold increase/decrease in
both cell lines as a cutoff level, four candidate genes (ISGF3G,
ETV5, ZNF133, CEBPG) were identified (Table 2). All four
cDNAs have been confirmed by sequencing, and the IFN-g-
mediated upregulation of all four genes as well as IFN-g-mediated
downregulation of S100A4 has been verified by Northern
blotting. Whether any of these four factors are involved in IFN-
__ _ _ ++ +
0 h 24 h 36h 48 h
__ _ _ ++ +
0 h 24 h 36 h 48 h
__ ++
48 h 72 h 48 h 72 h
__ ++
S100A4
S100A4
18S rRNA
STAT1
-Tubulin
OHS II-11b PM1 WiDr
A
B
Figure 2 Optimisation of the IFN-g response. (A) Northern blots showing transcriptional regulation of S100A4 in time–response experiments. OHS and
II-11b cells were incubated with 10Uml
 1 IFN-g, and WiDr and PM1 cells were incubated with 200Uml
 1 IFN-g. Expression of 18S rRNA serves as loading
control. (B) Western blots showing regulation of S100A4 and STAT1 by IFN-g in time–response experiments. Incubation conditions as in (A)
Immunostaining of a-tubulin serves as loading control.
__ ++ +
0′
STAT1-P
STAT1
5′ 15′ 30′ 30′
IFN-
Figure 3 Confirmation of active Jak/STAT1 signalling pathway. Western
blot stained with antiphospho-STAT1 (Tyr-701). OHS cells were treated
with 1000Uml
 1 IFN-g as indicated. Cells were harvested at indicated time
points and analysed by Western blotting as described in Materials and
Methods.
Table 1 Cell cycle distribution, proliferation and apoptosis in IFN-g treated cell cultures
Cell
line
IFN-c
(Uml
 1)
Hours of
treatment
% cells in
G0/G1 (s.d.) % cells in S (s.d.)
% cells
in G2/M (s.d.)
MTS assay
(proliferation)
% of control (s.d.)
Apoptosis fold
induction (s.d.)
OHS — 0 46 (7) 16 (6) 38 (7)
— 48 55 (10) 11 (6) 34 (11) 100 1
10 48 48 (3) 9 (4) 43 (7) 52 (15) 3.5 (2.4)
II-11b — 0 38 (6) 4 (11) 51 (10)
— 48 48 (7) 15 (7) 37 (4) 100 1
10 48 44 (6) 15 (2) 41 (5) 87 (13) 1.6 (0.6)
PM1 — 0 68 (4) 14 (5) 18 (1)
— 72 70 (8) 9 (5) 21 (4) 100 1
200 72 72 (7) 8 (3) 20 (7) 83 (5) 1 (0.1)
WiDr — 0 40 (12) 18 (6) 42 (11)
— 72 72 (7) 8 (4) 20 (7) 100 1
200 72 66 (9) 5 (5) 29 (12) 53 (8) 5.7 (0.1)
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investigation.
DISCUSSION
Transcriptional regulation of S100A4
Transcriptional regulation of S100A4 in response to treatment with
different signal inducers was examined in cell lines expressing
different levels of the protein. IFN-g-mediated downregulation of
S100A4 was observed in all the examined cell lines, but the
sensitivity varied with respect to dose and time of incubation.
When exposed to a low-dose IFN-g (and for a shorter incubation
period), STAT1 was induced in all four cell lines, indicating that
the receptor is present, and that the extent of S100A4 transcrip-
tional downregulation could not be attributed to a general
difference in IFN-g sensitivity.
Considering the fundamental biological effects induced by the
MAP kinase cascade, and also by TGF-b and TNF-a, it was
somewhat surprising that none of these signalling pathways
were found to modulate the transcription of S100A4. Several
studies have indicated that S100 proteins, due to their Ca
2þ-
binding properties, are involved in regulating intracellular
Ca
2þ homeostasis or Ca
2þ-dependent cell signalling (Boni
et al, 1997; Duarte et al, 1998). In addition, an intracellular
relocation of S100A4 upon treatment with thapsigargin has
been reported (Mueller et al, 1999). We did not, however,
observe any changes in S100A4 expression caused by thapsigargin,
indicating that no direct association between trans-
criptional regulation of S100A4 and Ca
2þ-dependent cell signal-
ling existed in our cell systems. In agreement with our results,
Takenaga (1999) showed that the expression of S100A4 in human
colon adenocarcinoma cell lines was regulated by IFN-g, but not
influenced by IL-1, IL-6, various growth factors or IFN-a and -b.
Taken together, the expression of S100A4 seems to be rather stable
in cancer cells, and one might suggest that signalling pathways
regulating S100A4 gene transcription in cultured cancer cells are
well defined, without extensive crosstalk between the different
pathways. Whether this is the case in cancer cells in vivo remains
to be investigated.
IFN-c induced apoptosis but no cell cycle arrest
IFN-g may inhibit cell proliferation and induce cell cycle arrest
and/or apoptosis through diverse mechanisms. Since no differ-
ences in cell cycle distribution between treated and control cell
cultures were revealed, we propose that downregulation of S100A4
expression could not be explained by IFN-g-mediated cell cycle
arrest.
Using an immunoreagent-based apoptosis detection kit, we
found that the two cell lines, OHS (high expression of S100A4) and
WiDr, were more susceptible to IFN-g-induced apoptosis (up to
five-fold increase) than the low S100A4 expressing II-11b and PM1
cell lines. Notably, the latter was completely resistant to IFN-g-
induced apoptosis. Recently, Grigorian et al (2001) reported a
significant inverse correlation between expression of wild-type p53
and S100A4 in a panel of tumour cell lines, and suggested that
S100A4 could cooperate with wild-type p53 in triggering apoptosis
(Grigorian et al, 2001). PM1 is the only cell line in our study
harbouring wild-type p53 (unpublished). According to our results,
wild-type p53 combined with a low expression of S100A4 protected
the cells against IFN-g-mediated apoptosis. Interestingly, II-11b
cells with a low expression of S100A4 were significantly less
susceptible to IFN-g-mediated apoptosis than the high expressing
counterpart, OHS. Whether these differences in induction of
0 12 24
+ _ + _ + _
S100A4
IFN-
18S rRNA
10 U ml
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Figure 4 Effect of IFN-g on S100A4 mRNA stability in OHS cells.
Northern blot analysis demonstrating S100A4 mRNA stability in OHS
control cultures and cultures treated with 10Uml
 1 IFN-g. The cultures
were incubated for 24h before the addition of 5mM actinomycin D. The
cells were then harvested at different time points as indicated. Isolation of
total RNA and Northern blotting were performed as described in Materials
and Methods. The chart is a graphical presentation of the band intensities as
measured by means of densitometric scanning. The figure shows one of
three independent experiments with similar results.
Table 2 Summary of microarray results
ID
number ID name Common name Function
a Ratio
b
724588 ISGF3G Interferon-stimulated
transcription factor 3
gamma, p48, IRF-9
Responsible for the initial stimulation of IFN-a- and b-responsive genes, it recognises and binds
to the IFN-stimulated response element, or ISRE within the regulatory sequences of target
genes. ISGF3 plays a primary role in the transmission of a signal from the cell surface to the
nucleus
9
796542 ETV5 ERM, ETS-related
protein
Binds to DNA sequences containing the consensus nucleotide core sequence ggaa 6
50794 ZNF133 Zinc-finger protein
133
May be involved in transcriptional regulation as a repressor 4
455121 CEBPG CCAAT/enhancer
binding protein
gamma
Transcription factor that binds to the enhancer element PRE-i (positive regulatory element-i) of
the IL-4 gene. Might change the DNA-binding specificity of other transcription factors and recruit
them to unusual DNA sites
4
aDescription of genes are modified from Rebhan et al. (1997). URL: http://bioinformatics.weizmann.ac.il/cards.
bOHS and II-11b cells treated with IFN-g (10Uml
 1,4 8h )vs
untreated control, average ratio from four hybridisations.
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S100A4 is currently under investigation. Importantly, expression
of S100A4 was downregulated in all four cell lines, independent of
the level of apoptosis. Based on this observation, we concluded
that the observed repression of S100A4 was not caused by IFN-g-
mediated apoptosis.
IFN-c mediated no change in S100A4 mRNA stability
The observed IFN-g-mediated downregulation of S100A4 might be
caused by decreased mRNA stability, or alternatively by repression
of transcriptional activity. In contrast to previous results
(Takenaga, 1999), treatment of the OHS cells with actinomycin D
revealed no significant difference in RNA stability upon the
addition of IFN-g. One possible explanation for this discrepancy is
that different cell lines were used. We concluded that in OHS cells,
IFN-g-mediated downregulation of S100A4 was most likely caused
by repression of S100A4 gene transcription and not a result of
decreased mRNA stability.
Candidate genes involved in repression of S100A4
transcription as revealed by microarray analysis
Our results indicated that the S100A4 promoter carries elements/
regions that are susceptible to IFN-g-mediated signalling. Notably,
the time gap between phosphorylation of STAT1 protein (within a
few minutes) and detectable reduction of S100A4 transcription
(24h) suggested that the latter response was not a direct effect of
STAT1 binding to elements in the S100A4 promoter. In line with
this, no IFN-GAS was found in the promoter comprising 2500 base
pairs (bp) upstream of ATG. Several other proteins may interact
with STAT1 and modulate its transcriptional activity, for example,
the histone acetyltransferases CBP/p300 and the tumour suppres-
sor BRCA1 (Zhang et al, 1996; Ouchi et al, 2000). It has also
recently been published that IFN-g may activate other signalling
pathways, like the MAP kinases, independent of STAT1 activation
(Gil et al, 2001; Ramana et al, 2001). This complex picture of
proteins involved in the regulation of IFN-g-induced gene
expression led us to perform microarray analysis in an attempt
to identify candidates participating in the observed repression of
S100A4 gene expression. We identified four genes, of which
ISGF3G (IRF-9/p48) was the most pronounced upregulated
transcript (nine-fold), while a member of the CCAAT-enhancer-
binding protein family, CEBP-gamma (CEBPG), was upregulated
four-fold. Notably, it was recently shown that another member of
the family (CEBPB) was transcriptionally induced by IFN-g, and
subsequently regulated the transcription of ISGF3G through the
IFN-g-activated transcriptional element (GATE) (Roy et al, 2002).
Members of the CEBP family have been shown to interact with
CBP/p300 and members of the Ets family of transcription factors
(Mink et al, 1997; McNagny et al, 1998). ETV5, which is an Ets
family member, was found to be upregulated more than six-fold in
our IFN-g-treated cells. ZNF133 has previously been associated
with transcriptional repression in other cell systems (Vissing et al,
1995). We were, however, not able to find binding sites for ZNF133
or ISGF3G when examining 1000bp upstream of the human
S100A4 translation start site. In contrast, several potential binding
sites for factors of the CEBP family, Ets family and p300 were
detected (Schug and Overton, 1997).
In conclusion, we have found that IFN-g downregulates S100A4
expression in osteosarcoma, breast and colon carcinoma cell lines.
Our results indicate that this downregulation was mediated by
inhibition of the S100A4 gene transcription, and not, as previously
reported, caused by the IFN-g-mediated decrease of S100A4 mRNA
stability. S100A4 transcriptional activity was repressed indepen-
dently of IFN-g-mediated apoptosis and cell cycle effects. There-
fore, we are currently investigating the S100A4 promoter in order
to identify responsible transcriptional elements and mechanisms
involved in IFN-g-mediated inhibition of S100A4 gene transcrip-
tion.
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